Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

$100bn biotechs like Vertex Pharmaceuticals (NDQ:VRTX) typically get to their position through 'blockbuster drugs' with periods of market exclusivity, which eventually come to an end and cause revenues to fall as cheaper biosimilars come onto the market. The average biotech is facing a loss of revenue of 38%. Of course, some are higher (i.e. Amgen…

ByNick SundichOctober 23, 2025

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

The dream run Pfizer had during the pandemic was not going to last forever. But while certain companies that derived a windfall during the pandemic (one example being Sonic (ASX:SHL)) had decent businesses pre-COVID and began to 'normalise' post-pandemic, Pfizer has continued to decline (shares have dropped another 12% in 2025). What are the Best ASX…

ByNick SundichOctober 13, 2025

PainChek (ASX:PCK): Investors dreamed 2025 would be the year it finally enters the US market, and their dreams are becoming a reality!

PainChek (ASX:PCK) has among the most admirable medical technologies there is, in the form of an app that can detect pain in non-verbal patients. Unfortunately, there has been pain for investors along the way. When it was announced that it was participating in a clinical trial the Morrison government was investing $5m in back in 2019,…

ByNick SundichOctober 8, 2025

Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism

Cyclopharm (ASX:CYC) is a rare species - an ASX stock that is approved in the US market. However, its share price has gone in the opposite direction. Cyclopharm has not had as fast an uplift as other companies have had and still makes most of its sales from other jurisdictions. A lawsuit from 4D Medical…

ByNick SundichOctober 8, 2025

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Hear the term 'Activist investors' and you might think of GetUp, the progressive activist group that forced Woolworths to hold an EGM in 2014 in an attempt to limit the maximum bets on poker machines to $1. Or perhaps even of ESG-focused fundies like Australian Ethical (ASX:AEF). The reality is a lot more complicated and…

ByNick SundichOctober 8, 2025

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Proteomics' suite of Promarker tests are all being launched in 2025. The range includes: PromarkerD for DKD which has been launched in Australia and the USA; PromarkerEso for Esophageal cancer which is now commercially available in Australia, and PromarkerEndo for Endometriosis which will be commercialised shortly. Launching 3 tests in a a year is…

ByNick SundichSeptember 26, 2025

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Amplia Therapeutics (ASX:ATX) is another ASX oncology biotech company, attempting to battle cancer. At first glance, it may not a unique company but when you dig deeper...it is. It is using an 'FAK inhibitor' to fight pancreatic cancer (and potentially other indications down the track). What are the Best ASX Stocks to invest in right now?…

ByNick SundichSeptember 23, 2025

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

There's another company about to join the cohort of ASX biotech stocks and its name is Nexsen. Nexsen is proposed to list on Tuesday October 7, raising $6m at 20c per share, and to have the code NXN. This company has a rapid sensing technology that it will first commercialise to detect Group B Streptococcus…

ByNick SundichSeptember 19, 2025

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

When Perth-based Emyria (ASX:EMD) announced on 18 June that Medibank would be funding eligible customer participation in Emyria's Post-Traumatic Stress Disorder care programme, with no out-of-pocket costs, investors who know the Life Sciences sector needed to sit up and take notice. Here was Australia's largest health insurer, with over 4.2 million customers, saying that it…

ByStuart RobertsSeptember 10, 2025

Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?

Actinogen Medical (ASX:ACW) is the poster child for how volatile biotech stocks can be. the last time we wrote about this company was in August last year when shares more than halved after results of a Phase II trial that investors perceived to be a flop. But the company has soldiered on and has a…

ByNick SundichSeptember 9, 2025

the Kick-ass Multipurpose WordPress Theme

Life Sciences

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

PainChek (ASX:PCK): Investors dreamed 2025 would be the year it finally enters the US market, and their dreams are becoming a reality!

Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine

Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Life Sciences

Stocks in Spotlight

Add Your Heading Text Here